ERK5 is activated by oncogenic BRAF and promotes melanoma growth

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling Pathways

Background:

• Malignant melanoma is an aggressive cancer with increasing incidence.
• Current targeted therapies and immunotherapies show limitations for metastatic melanoma.
• The role of the MEK5-ERK5 pathway in melanoma is largely unexplored compared to BRAF-MEK1/2-ERK1/2.

Purpose of the Study:

• To investigate the function and therapeutic potential of the ERK5 signaling pathway in melanoma.
• To determine the relationship between BRAF signaling and ERK5 activity in melanoma cells.
• To evaluate ERK5 inhibition as a potential treatment strategy for melanoma.

Main Methods:

• Analysis of ERK5 expression and activity in human melanoma tissues and cell lines.
• Genetic silencing and pharmacological inhibition of the ERK5 pathway.
• Assessment of melanoma cell and xenograft growth following pathway inhibition.
• Investigation of the interplay between BRAF and ERK5 signaling.
• Combination therapy studies involving BRAF, MEK5, and ERK5 inhibitors.

Main Results:

• ERK5 is consistently expressed and active in melanoma cells.
• Inhibition of ERK5 signaling significantly reduces melanoma cell and xenograft growth.
• Oncogenic BRAF positively regulates ERK5 expression, phosphorylation, and nuclear localization.
• Combined inhibition of BRAF and MEK5 is necessary to decrease nuclear ERK5, essential for proliferation.
• Combination therapies targeting ERK5 and BRAF/MEK1/2 demonstrate enhanced efficacy.

Conclusions:

• The ERK5 pathway plays a critical role in melanoma growth both in vitro and in vivo.
• Targeting ERK5, either as a single agent or in combination with existing therapies, represents a novel therapeutic approach for melanoma.
• Understanding the BRAF-ERK5 axis provides new insights into melanoma pathogenesis and treatment strategies.